U.S. licenses key Covid vaccine technology to WHO so other countries can develop shots
· The NIH has licensed its stabilized spike protein technology to the WHO, President Joe Biden said.
· The technology is key component of the current Covid-19 vaccines.
· The spike protein is the component in the vaccines that induces an immune response, prompting the body to fight the virus.
· The license would help the WHO work with manufacturers around the world to produce their own Covid-19 vaccines.
Spencer Kimball, CNBC
May 12 2022
President Joe Biden on Thursday said the U.S. has licensed a key technology used in the current Covid-19 vaccines to the World Health Organization, which would allow manufacturers around the world to work with the global health agency to develop their own shots against the virus.
The National Institutes of Health has licensed its stabilized spike protein technology to the WHO and United Nations’ Medicines Patent Pool, Biden said.
The spike protein is the component in the vaccines that induces an immune response, prompting the body to fight the virus. The NIH technology holds the proteins in a configuration that allows them to produce a more potent immune response. The WHO and the Medicines Patent Pool can now sublicense the technology to generic manufacturers around the world.
“We are making available health technologies that are owned by the United States government, including stabilized spike protein that is used in many Covid-19 vaccines,” Biden said.
The decision to share the vaccine technology comes ahead of a virtual global Covid-19 summit that the U.S. is co-hosting Thursday. The WHO, in a statement, said the license would make the crucial technology accessible to people in low and middle-income countries and help end the pandemic...
more, including links